Arthritis patients resort to an inconvenient Medicare workaround to avoid pricey drugs
As many as 40,000 chronically ill seniors are choosing to endure uncomfortable, time-consuming intravenous infusions because Medicare doesn’t sufficiently cover far more convenient, and less distressing, at-home treatments with the arthritis drug Humira.
When rheumatoid arthritis patients enroll in Medicare, switching from private insurance plans, self-administered medications such as Humira and Xeljanz become unaffordable overnight, thanks to the program’s convoluted pricing of at-home prescription drugs. To reduce patients’ out-of-pocket expenses, rheumatologists often suggest a workaround: regular, hour-plus visits to a hospital or infusion center for intravenous drug treatments.
